Figure adapted from Sandborn WJ, Su C, Sands BE, et al; for the OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736.

The recommended dose for maintenance treatment is XELJANZ® 5 mg BID. When induction treatment is complete, the dosage should be decreased from 10 mg BID to 5 mg BID.²

• The primary efficacy endpoint in the OCTAVE Induction 1 and 2 trials was remission at week 8, and in the OCTAVE Sustain trial, it was remission at week 52^1,c
• The XELJANZ induction and maintenance trials incorporated a more rigorous definition of remission that required the absence of any rectal bleeding (Mayo subscore of 0), unlike previous clinical trials for treatments of UC¹
• ​​​​​​​Patients who completed one of the OCTAVE Induction studies but did not achieve clinical response or patients who completed or withdrew early due to treatment failure on XELJANZ or placebo in the maintenance study were eligible for the open-label extension study. OCTAVE Open is a safety and tolerability study¹​​​​​​​
• ​​​​​​​Patients were assessed using the Mayo scale, a tool for evaluating disease activity in UC patients that is composed of 4 subscores (stool frequency, rectal bleeding, endoscopic findings, and Physician’s Global Assessment), each with a range of 0 to 3 (higher scores indicate more severe disease)¹

Figure adapted from Sandborn WJ, Su C, Sands BE, et al; for the OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736.